Hangzhou Biotest Biotech Co.,Ltd.
688767
Rank in Stocks
#9399
Hangzhou Biotest Biotech Co., LTD. is an enterprise focused on the research,... Hangzhou Biotest Biotech Co., LTD. is an enterprise focused on the research, development, manufacturing, sales, and servicing of in vitro diagnostic (IVD) solutions. Operating both domestically within China and across international markets, the company provides a comprehensive range of medical testing products. Their offerings span crucial health areas including reproductive health, cancer detection, cardiovascular conditions, inflammatory markers, biochemical analysis, and various infectious diseases. This extensive portfolio also encompasses rapid diagnostic tests for COVID-19 (covering both antibody and antigen detection), as well as screening kits for drug use (utilizing urine, saliva, and hair samples) and assessing vitamin D levels. Beyond diagnostic kits and reagents, Hangzhou Biotest Biotech also supplies essential accompanying equipment, such as immunochromatography readers and fluorescence immunoassay quantitative analyzers. The company, established in 2008, is based in Hangzhou, China.
Share Price
$5.74
Last synced: 2026-11-10
Market Cap
$857.13M
Change (1 day)
0.71%
Change (1 year)
-6.56%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Hangzhou Biotest Biotech Co.,Ltd. (688767)
Category
Healthcare
Operating Margin for Hangzhou Biotest Biotech Co.,Ltd. (688767)
Operating Margin as of November 2026 TTM: 3.06%
According to Hangzhou Biotest Biotech Co.,Ltd.'s latest financial reports, its current operating margin (TTM) is 3.06%. At the end of 2025 the company had an operating margin of 2.50%.
Operating Margin history for Hangzhou Biotest Biotech Co.,Ltd. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 3.06% | 22.40% |
| 2025 | 2.50% | -92.77% |
| 2024 | 34.57% | 30.85% |
| 2023 | 26.42% | -45.06% |
| 2022 | 48.09% | -9.54% |
| 2021 | 53.16% | -10.34% |
| 2020 | 59.29% | 284.25% |
| 2019 | 15.43% | 23.34% |
| 2018 | 12.51% | 257.43% |
| 2017 | 3.50% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -87.39% |
US
|
|
| -149.01% | -148.70% |
US
|
|
| 25.57% | -91.64% |
AU
|
|
| 31.23% | -89.79% |
BE
|
|
| 29.35% | -90.41% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Hangzhou Biotest Biotech Co.,Ltd.'s operating margin
What is Hangzhou Biotest Biotech Co.,Ltd.'s operating margin?
Hangzhou Biotest Biotech Co.,Ltd.'s operating margin is 3.06%, as of Nov 2026.
What was Hangzhou Biotest Biotech Co.,Ltd.'s operating margin in 2025?
In 2025, Hangzhou Biotest Biotech Co.,Ltd.'s operating margin was 2.50%, compared with 34.57% in 2024.
How has Hangzhou Biotest Biotech Co.,Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Hangzhou Biotest Biotech Co.,Ltd.'s operating margin was highest in 2020 (59.29%) and lowest in 2025 (2.50%).
How does Hangzhou Biotest Biotech Co.,Ltd.'s operating margin compare with similar companies?
Hangzhou Biotest Biotech Co.,Ltd.'s operating margin (3.06%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.